Literature DB >> 33359267

Proton beam therapy reduces the risk of severe radiation-induced lymphopenia during chemoradiotherapy for locally advanced non-small cell lung cancer: A comparative analysis of proton versus photon therapy.

Nalee Kim1, Jae Myoung Noh1, Woojin Lee1, Byoungsuk Park1, Heejoo Park1, Ji Young Park1, Hongryull Pyo2.   

Abstract

HYPOTHESIS: We investigated differences in severe radiation-induced lymphopenia (SRL) after pencil beam scanning proton therapy (PBSPT) or intensity-modulated (photon) radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer.
METHODS: We retrospectively reviewed 223 patients who received definitive concurrent chemoradiotherapy with PBSPT (n = 29) or IMRT (n = 194). SRL was defined when ≥2 events of absolute lymphocyte counts (ALCs) of <200 cells/μL were observed in weekly laboratory tests conducted during treatment. Stepwise multivariate logistic regression with 10-fold cross-validation was performed to identify predictive values of SRL. Furthermore, 1:2 propensity score matching (PSM) analysis was performed between the PBSPT and IMRT groups.
RESULTS: Baseline ALC was comparable between the PBSPT and IMRT groups (median, 2130 vs. 2040 cells/μL; p = 0.983). Lung volumes receiving ≥ 5-20 GyE and the mean dose were significantly lower in patients receiving PBSPT than those receiving IMRT (p < 0.001). Among 72 (32.3%) patients with SRL; 69 (95.8%) and 3 (4.2%) patients were treated with IMRT and PBSPT, respectively. After multivariable analysis, PBSPT reduced SRL compared to IMRT (odds ratio [OR] 0.13, p = 0.003). Specifically, lung V5Gy were identified as the strongest predictor of SRL before (OR 1.11) and after PSM (OR, 1.07) (p < 0.05). With a median follow-up of 23.0 months, the 2-year overall survival in patients with SRL was worse than that those without SRL (63.4% vs. 79.9%; p = 0.003).
CONCLUSIONS: Reduced irradiated lung volumes of PBSPT consequently reduced SRL. In addition, lung V5Gy contributed to the SRL. Reduction of SRL through the optimized RT might be essential to improve the outcomes.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lung cancer; Lymphopenia; Proton beam therapy; Radiation therapy

Year:  2020        PMID: 33359267     DOI: 10.1016/j.radonc.2020.12.019

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

Review 1.  National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States.

Authors:  Arnold Pompos; Robert L Foote; Albert C Koong; Quynh Thu Le; Radhe Mohan; Harald Paganetti; Hak Choy
Journal:  Front Oncol       Date:  2022-06-14       Impact factor: 5.738

2.  HEDOS-a computational tool to assess radiation dose to circulating blood cells during external beam radiotherapy based on whole-body blood flow simulations.

Authors:  Jungwook Shin; Shu Xing; Lucas McCullum; Abdelkhalek Hammi; Jennifer Pursley; Camilo A Correa; Julia Withrow; Sean Domal; Wesley Bolch; Harald Paganetti; Clemens Grassberger
Journal:  Phys Med Biol       Date:  2021-08-03       Impact factor: 4.174

3.  Physics and biomedical challenges of cancer therapy with accelerated heavy ions.

Authors:  Marco Durante; Jürgen Debus; Jay S Loeffler
Journal:  Nat Rev Phys       Date:  2021-09-17

Review 4.  Imaging Strategies in Proton Therapy for Thoracic Tumors: A Mini Review.

Authors:  Carlo Algranati; Lidia Strigari
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

5.  Prediction and clinical impact of delayed lymphopenia after chemoradiotherapy in locally advanced non-small cell lung cancer.

Authors:  Byung-Hee Kang; Xue Li; Jaeman Son; Changhoon Song; Hyun-Cheol Kang; Hak Jae Kim; Hong-Gyun Wu; Joo Ho Lee
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

6.  The Feasibility of Stereotactic Body Proton Beam Therapy for Pancreatic Cancer.

Authors:  Hyunju Shin; Jeong Il Yu; Hee Chul Park; Gyu Sang Yoo; Sungkoo Cho; Joon Oh Park; Kyu Taek Lee; Kwang Hyuck Lee; Jong Kyun Lee; Joo Kyung Park; Jin Seok Heo; In Woong Han; Sang Hyun Shin
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

7.  Substantial Sparing of Organs at Risk with Modern Proton Therapy in Lung Cancer, but Altered Breathing Patterns Can Jeopardize Target Coverage.

Authors:  Camilla Grindeland Boer; Kristine Fjellanger; Inger Marie Sandvik; Maren Ugland; Grete May Engeseth; Liv Bolstad Hysing
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.